UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of October 2020
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jeusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On October 1, 2020, BiondVax Pharmaceuticals Ltd. (the “Company”) entered into an ATM Equity OfferingSM Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc. and Credit Suisse Securities (USA) LLC (collectively, the “Agents”) pursuant to which the Company may offer and sell American Depositary Shares (the “ADSs”), each representing 40 ordinary shares, no par value of the Company (the “Shares”), having aggregate gross sales proceeds not to exceed $100 million, from time to time, through an “at the market” offering program. The ADSs will be offered and sold through the Agents acting as sales agents. The Company may also sell ADSs directly to any of the Agents acting as principal for its own account, in which case the Company will enter into a separate terms agreement with such Agent. Any ADSs that may be sold pursuant to the Sales Agreement will be issued pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-240189), as supplemented by the prospectus supplement dated October 1, 2020 relating to the sale of the Shares.
The Company is not obligated to sell any ADSs pursuant to the Sales Agreement. A copy of the Sales Agreement is attached as Exhibit 1.1. The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
Exhibit Index
This Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statement on Form F-3 (Registration No. 333-240189) and its Registration Statement on Form S-8 (Registration No. 333-239344).
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BiondVax Pharmaceuticals Ltd. | ||
Date: October 1, 2020 | By: | /s/ Ron Babecoff |
Ron Babecoff | ||
Chief Executive Officer |
2